AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Oracle CEO: "If we continue on our current trajectory, reaching a valuation of a trillion dollars is inevitable"
2
Is your solitaire opponent actually a bot?
3
Once $5 billion IPO bound, Cybereason merges with Trustwave amid decline
4
"The next phase for Miami will be an increase in exits"
5
Cloudera acquires Israeli startup Octopai to advance metadata and AI integration
More news

Drugs

20 stories about Drugs
חנות מריחואנה קולורדו קנאביס

Bill to Decriminalize Marijuana Use Advances in Israeli Parliament

08.03.18|Shahar Ilan
Fines and volunteer service would replace criminal charges for first-time offenders under the proposed law
תרופות טבע גלולות תרופה

Teva to Repay Due Loans with Junk Bond Private Offering

01.03.18|Lilach Baumer
The debt-laden generic drugmaker is offering around $3.5 billion in senior notes in both dollar and euro denominations
מוסף שבועי 22.12.16 חממה לגידול קנאביס של חברת Breath of Life

Israel’s Cannabis Fever: Six Stories From Israel’s Growing Medical Marijuana Hub

18.02.18|CTech
Activity in the segment of cannabis-related technologies and medical cannabis has been on the rise in recent years in Israel
וורן באפט 2017 ברקשייר האתוויי

Berkshire Hathaway Takes Position in Generic Drugmaker Teva

15.02.18|Lilach Baumer
The holding company disclosed a $358 million stake in the struggling company
מנכ"ל טבע החדש קור שולץ

Generic Drugmaker Teva Says Profit Will Continue to Drop in 2018

08.02.18|Dror Reich
Israel’s Teva reports a $17-billion goodwill impairment citing the decline of the U.S. generic market
חממה של BOL קנאביס

Fearing Leakage of Medical Cannabis to Recreational Users, Israel’s Ministry of Public Security is Delaying Export Licensing

05.02.18|Sefi Krupsky
Export regulations are part of a wider planned cannabis reform announced in 2016, aiming to legalize and monitor medical cannabis products in the country
עובדי מפעל טבע נתניה

Moody’s Downgrades Teva Bond Rating to “Junk”

14.01.18|Lilach Baumer
The credit rating agency is following is the steps of Fitch, which did the same in November. Of the “big three,” only S&P Global still rates Teva as investment grade
מנכ"ל טבע החדש קור שולץ 2

As Part of Cost-Cutting Plan, Teva Will Shut Down Twenty or More Manufacturing Sites

10.01.18|Lilach Baumer
The drugmaker will shut down 20-25 manufacturing sites in the next two years, CEO Kåre Schultz said Monday
מנכ"ל טבע החדש קור שולץ 2

As U.S. Domestic Issuer, Teva Reveals Top Stock Owners

03.01.18|Dror Reich
Kåre Schultz, the newly-appointed CEO of generic drugmaker Teva Pharmaceutical Industries Ltd., is one of Teva's largest shareholders, a Wednesday filing to the U.S. Securities and Exchange Commission revealed
שם: מעבדה ביוטק וושי אפטק Lab Biotech WuXi AppTec

Merck, China’s WuXi AppTec to Launch Biotech Incubator in Israel

25.12.17|Meir Orbach
Israel-born businessman Mori Arkin and life sciences-focused venture capital fund Pontifax are also partners in the venture, set to launch in 2018
default image

Following Restructuring Announcements, Teva Reinstated as Israel’s Biggest Company

18.12.17|Lilach Baumer
Teva's stock jumped 18.7% on the New York Stock Exchange between Thursday market opening and Friday market close. Israeli Prime Minister Benjamin Netanyahu is expected to meet with CEO Kåre Schultz Tuesday
מנכ"ל טבע החדש קור שולץ

Teva Might Have Been Better Off as a Smaller Company, new CEO Says

17.12.17|Dror Reich
The generic drugs powerhouse is now carrying a $34.7 billion debt—a result of a $40.5 acquisition of Actavis. New CEO Kåre Schultz presented a detailed restructuring plan on Thursday
אחרי ה שביתה נתב"ג טבע פיטורים טיסות טרמינל

Tel Aviv Airport, Stock Market Open as Solidarity Strike Ends

17.12.17|Lior Gutman, Omri Milman and Micky Grunfeld
Israel’s largest labor union called for a half-day strike on Thursday, in support of Teva employees
פסקל סוריו מנכ"ל AstraZeneca

Once Future CEO Could have Taken Teva on a Different Path

14.12.17|Lilach Baumer, Golan Hazani, and Orr Hirschauge
AstraZeneca CEO Pascal Soriot, which backed out of Teva’s CEO position in July, planned on taking the company towards innovation instead of generic focus
מנכ"ל טבע החדש קור שולץ 2

Teva to Cut Around Half of Israeli Workforce, Outsource Operations

13.12.17|Dror Reich
An internal document reviewed by Calcalist reveals the troubled drugmaker's detailed domestic cost-cutting plans
מפעל טבע טק ב רמת חובב

Teva to Cut Jobs, Shut Down Some Israeli Operations

13.12.17|Dror Reich and Sefi Krupsky
On Thursday, the troubled drugmaker is expected to unveil its cutback plan. At its center is extensive layoffs and the reorganization and divestment of non-core assets
יצחק פטרבורג

Former Chairman Yitzhak Peterburg Leaves Teva

13.12.17|Lilach Baumer
Mr. Peterburg was the troubled drugmaker's interim CEO between February and November 1, when Kåre Schultz took helm
מנכ"ל טבע החדש קור שולץ 1

Teva to Unveil Strategic Plan, Layoffs Thursday

12.12.17|Dror Reich
Last month the debt-riddled drug maker announced a rehabilitation plan amidst rumors of upcoming employee cuts
מייסד קייט פארמה אריה בלדגרין

Gilead Builds on Kite Pharma Acquisition, Buys Second CAR-T Therapy Company

10.12.17|Lilach Baumer
California-based Cell Design Labs will be acquired in a deal valued at up to $567 million
חברת ה תרופות טבע Teva

Fresh Teva Lawsuit Goes Against Dividends Paid by Debt Heavy Drugmaker

30.11.17|Anat Rouah
Tel Aviv-based capital investment firm Tulip Capital is threatening derivative action against Teva, saying the company's huge debt load renders its dividends unlawful
Previous ArticlesMore Articles